Theravance Biopharma Inc expected to post a loss of 15 cents a share - Earnings Preview

Theravance Biopharma

23/02/2024 21:29

* Theravance Biopharma Inc  TBPH.OQ   TBPH.O  is expected
to show
a rise in quarterly revenue when it reports  results on February
26 for the period ending December 31 2023
    * The George Town Grand Cayman-based  company is expected to
report a 20.7% increase in revenue to $17.684 million from
$14.65 million a year ago, according to the mean estimate from 3
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Theravance Biopharma Inc
is
for a loss of 15 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Theravance
Biopharma Inc is $12.50​, above​ its last closing price
of $8.68. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.22       -0.21      -0.17     Beat    18.9
 Jun. 30 2023  -0.22       -0.21      -0.28     Missed  -33.3
 Mar. 31 2023  -0.25       -0.25      -0.35     Missed  -42.1​
 Dec. 31 2022  -0.17       -0.17      -0.15     Beat    13
 ​​Sep.        -0.21       -0.18      -0.21     Missed  -15.1
 30 2022                                                
 Jun. 30 2022  0.09        0.11       -0.09     Missed  -182.6
                                                        ​
 Mar. 31 2022  -0.11       -0.11      -0.22     Missed  -107.5
 Dec. 31 2021  -0.32       -0.33      -0.43     Missed  -29.7
 This summary was machine generated February 23 at 21:29 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)